Global Hepatitis C Drugs Market 2019-2023 | Evolving Opportunities with AbbVie and Gilead | Technavio
LONDON--(BUSINESS WIRE)--Jan 8, 2020--
Technavio has been monitoring the global hepatitis C drugs market and the market is poised to post a decremental growth of USD -5.72 billion during 2019-2023. Request Free Sample Pages
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005281/en/
Technavio has announced its latest market research report titled global hepatitis C drugs market 2019-2023. (Graphic: Business Wire)
Read the 125-page research report with TOC on “Hepatitis C Drugs Market Analysis Report by Product (Combination therapy and Monotherapy), by Type (Acute hepatitis C and Chronic hepatitis C), by Geography (APAC, EMEA, and Americas), and Segment Forecasts, 2019 - 2023”.
The high prevalence of hepatitis C and increasing number of voluntary licensing agreements are anticipated to boost the growth of the market.
Individuals addicted to opioids and patients on parenteral therapy are highly susceptible to hepatitis C as it is a blood-borne infection. Lack of awareness about hepatitis C disease in developing countries is leading to an increase in the death rate. In developed countries, almost half of the patients with hepatitis C remain undiagnosed. In addition, the prevalence of hepatitis C is higher among males than females. All these factors are driving the need for better diagnosis of hepatitis C and the prescription of hepatitis C drugs by physicians. Thus, the high prevalence of hepatitis C is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Hepatitis C Drugs Market Companies:
AbbVie is headquartered in the US and operates the business under the Pharmaceutical products segment. The company offers MAVYRET, which is indicated for the treatment of adult patients with chronic hepatitis C.
Bristol-Myers Squibb is headquartered in the US and offers products through the Biopharmaceuticals business unit. The company offers DAKLINZA, which is indicated for the treatment of patients with chronic HCV genotype 1 or genotype 3 infection.
F. Hoffmann-La Roche
F. Hoffmann-La Roche is headquartered in Switzerland and operates under various business segments, namely Pharmaceuticals and Diagnostics. The company offers COPEGUS, which is indicated in combination with PEGASYS for the treatment of patients with chronic HCV infection.
Gilead is headquartered in the US and offers products through the Biopharmaceuticals business segment. The company offers HARVONI, EPCLUSA, and SOVALDI.
Merck is headquartered in the US and offers products through the following business segments: Pharmaceutical and Other segments. The company offers ZEPATIER, which is indicated for the treatment of chronic hepatitis C genotype 1 or 4 infection in adults.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Hepatitis C Drugs Product Outlook (Revenue, USD Million, 2019 - 2023)
Hepatitis C Drugs Regional Outlook (Revenue, USD Million, 2019 - 2023)
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report
Related Reports on Health Careinclude:
Alcoholic Hepatitis Treatment Market – Global Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200108005281/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: INFECTIOUS DISEASES PHARMACEUTICAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2020.
PUB: 01/08/2020 05:30 AM/DISC: 01/08/2020 05:30 AM